Pharma Equity Group (PEG) Fair Value & Analysis
Healthcare · DK · Market cap 100M DKK
Fair value as of: Jul 16, 2026
From 1 valuation models · updated today
Share price −6.8% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.0652 – kr 0.1480 · fair‑value band kr 0.0265 – kr 0.0404 · the kr 0.0820 price screens above the kr 0.0335 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pharma Equity Group (PEG) currently trades at kr 0.0820, while our model-based Fair Value estimate is kr 0.0335, implying the stock looks roughly 59.2% overvalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
It earns a return on equity of -87.3%. Net debt stands at 7.6M DKK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 0.0265 (bear case) to kr 0.0404 (bull case); at kr 0.0820, the current price sits above that range. The share trades about 45% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -59%, PEG screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma that are in Phase II clinical trials. The company was incorporated in 2002 and is headquartered in Horsholm, Denmark.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharma Equity Group reported revenue of kr 0 in FY2025 versus kr 0 in FY2021. Reported net income was −kr 25.4M in FY2025.
Is PEG fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharma Equity Group (PEG) undervalued?
What is the fair value of PEG?
What is the quality score of PEG?
What is the net profit margin of PEG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Pharma Equity Group reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Pharma Equity Group materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.